GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alk-Abello AS (OCSE:ALK B) » Definitions » Net Income (Continuing Operations)

Alk-Abello AS (OCSE:ALK B) Net Income (Continuing Operations) : kr690 Mil (TTM As of Jun. 2024)


View and export this data going back to 2005. Start your Free Trial

What is Alk-Abello AS Net Income (Continuing Operations)?

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Alk-Abello AS's Net Income (Continuing Operations) for the three months ended in Jun. 2024 was kr201 Mil. Its Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Jun. 2024 was kr690 Mil.

Alk-Abello AS Net Income (Continuing Operations) Historical Data

The historical data trend for Alk-Abello AS's Net Income (Continuing Operations) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alk-Abello AS Net Income (Continuing Operations) Chart

Alk-Abello AS Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Income (Continuing Operations)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -50.00 25.00 219.00 335.00 486.00

Alk-Abello AS Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Net Income (Continuing Operations) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 66.00 117.00 140.00 232.00 201.00

Alk-Abello AS Net Income (Continuing Operations) Calculation

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period.

Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr690 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alk-Abello AS  (OCSE:ALK B) Net Income (Continuing Operations) Explanation

Net Income (Continuing Operations) excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Alk-Abello AS Net Income (Continuing Operations) Related Terms

Thank you for viewing the detailed overview of Alk-Abello AS's Net Income (Continuing Operations) provided by GuruFocus.com. Please click on the following links to see related term pages.

Alk-Abello AS Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alk-Abello AS (OCSE:ALK B) » Definitions » Net Income (Continuing Operations)
Comparable Companies
OCSE:ZEAL OCSE:BAVA OCSE:GUBRA OCSE:PEG OCSE:GMAB OCSE:NOVO B VRTX REGN ASX:CSL XKRX:207940 MRNA XKRX:068270 XBRU:ARGX XBRU:UCB BNTX ALNY BGNE BMRN SZSE:300122 RPRX
Traded in Other Exchanges
AKBLF:USA 0OIR:UK 4AJ0:Germany
Address
Boge Alle 6-8, Horsholm, DNK, DK-2970
Website
https://www.alk.net
Alk-Abello A/S is a biotechnology company that focuses on pharmaceutical prevention, diagnosis, and treatment of allergies. The company is focused on respiratory diseases, including allergic rhinitis and allergic asthma. Moreover, the firm specializes in venom immunotherapy for patients suffering from bee and wasp allergies. The company's treatments induce a protective immune response that provides sustained symptom relief. Its primary focus is on allergy patients whose disease is not well controlled, despite the use of symptom-relieving medication.

Alk-Abello AS Headlines

No Headlines